Second Product Candidate to Receive an IND Clearance in Less Than 12 Months PRINCETON, New Jersey – June 27, 2018 – Oyster Point Pharma, Inc., a clinical-stage pharmaceutical company, today... read more →
Oyster Point Pharmaceuticals Inc., which is developing novel therapies for dry eye and other diseases of the ocular surface, today announced the completion of a $22 million Series A financing... read more →